ALMR · Nasdaq · USD · Market cap $2.4B · 222 employees
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
PASS · Titan Ethical · score 70.0Screen close, 2026-09-21 · not a live quote
Last reviewed 11 days ago
Screened 2026-09-21 · the tape above runs as of 19:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
A price-versus-fair-value chart appears here once we hold enough history for this name.
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alamar Biosciences, Inc. holds its Accumulation at $35.05. Consolidating, no directional conviction, held for 5 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $35.05 |
| Valuation | N/A trailing · -54.16 forward price to earnings |
| Values screen | PASS · score 70.0 |
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 29.63% | Below 33% | Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 30.54% | Below 49% | Money owed to the company is 30.5% of assets, under the 49% limit. | Pass |
| Revenue purity | 2.91% | Below 5% | Only 2.9% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadAlamar Biosciences, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-02. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthFair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 3.0% above the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits −3% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsImagine a blood test that spots disease proteins years before symptoms appear. Alamar Biosciences is racing to build that with its NULISA platform, selling instruments and consumables into a market hungry for better diagnostics. Revenue is doubling each year at 99 percent, the shares trade below our calculated fair value, and the business clears our ethical screen without issue.
Yet the numbers still give pause. Margins sit at minus 50 percent, the forward multiple is deeply negative, and no clear moat protects the technology from larger rivals. Five analysts call it a buy with a 32 dollar median target, but that optimism rests on forecasts that have yet to turn into sustained profits.
High growth in medical tools often masks how long it takes to reach scale and steady cash flow. We therefore pass. Analysis, not advice.
| Forward P/E | -54.2x |
| EPS, trailing | -0.72 |
| EPS, forward | -0.54 |
| Revenue growth | +82.1%growing very fast |
| Profit margin | -49.5%currently unprofitable |
| Debt to equity | 0.16minimal debt: a conservative balance sheet |
| Current ratio | 11.85comfortably covers its short-term bills |
| Short interest, float | 0.05% |
| 52-week range | 18.85 - 38.54 |
| Market cap | $2.4B |
| Employees | 222 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeALMR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. The street (5 analysts) rates it none, with a mean price target of $30.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.88 | -10.5% | · | $895 | -10.5% |
Historical returns from market close data. Past performance does not guarantee future results.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.
Get our weekly market brief free.